Format

Send to

Choose Destination
Minerva Endocrinol. 2017 Dec;42(4):385-396. doi: 10.23736/S0391-1977.16.02514-1. Epub 2016 Sep 14.

Ruminant trans-fatty acids and risk of breast cancer: a systematic review and meta-analysis of observational studies.

Author information

1
Student Research Committee, Faculty of Public Health Branch, Iran University of Medical Sciences, Tehran, Iran.
2
Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran.
3
Department of Community Nutrition, School of Nutritional Sciences and Dietetic, Tehran University of Medical Sciences, Tehran, Iran.
4
Cellular and Molecular Biology Department, International Kish Campus, University of Tehran, Tehran, Iran.
5
Student Research Committee, Faculty of Public Health Branch, Iran University of Medical Sciences, Tehran, Iran - shidfar.f@iums.ac.ir.

Abstract

INTRODUCTION:

Ruminant trans-fatty acids, especially cis9, trans11-conjugated linoleic acid (c9,t11-CLA) and trans11-18:1 vaccenic acid (t11-18:1 VA) appear to have anticarcinogenic activity against breast cancer in animal and in vitro experiments. However, the results remain inconsistent. We therefore conducted a systematic review and meta-analysis to assess the association of c9,t11-CLA, and t11-18:1 VA (intake or serum levels) with breast cancer risk.

EVIDENCE ACQUISITION:

Relevant studies were identified by a search of PubMed, OVID, SCOPUS and Google scholar databases through 25 May 2015. We included case-control and cohort studies that reported relative risk (RR) estimates with 95% confidence intervals (CIs) for the association between c9,t11-CLA and t11-18:1 VA intake or their serum levels and the risk of breast cancer. This meta-analysis was conducted according to the guidelines for the meta-analysis of observational studies in epidemiology.

EVIDENCE SYNTHESIS:

Three studies on c9,t11-CLA and t11-18:1 VA serum levels and t11-18:1 VA intake were evaluated in the systematic review only (narrative synthesis) and four studies (2 case-control and 2 cohort studies on c9,t11-CLA intake) were included in the meta-analysis (quantitative synthesis). The pooled RR for the highest vs lowest category of c9,t11-CLA intake was 0.94 (95% CI: 0.64-1.25) with evidence of heterogeneity (with 67,533 participants, I2=78.3%, P=0.003). Studies that could not be included in the quantitative syntheses were inconclusive.

CONCLUSIONS:

No association was found between c9,t11-CLA intake and breast cancer risk, but the number of studies identified was small.

PMID:
27627219
DOI:
10.23736/S0391-1977.16.02514-1
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Minerva Medica
Loading ...
Support Center